Upcoming Investor Conferences for Tyra Biosciences
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company dedicated to crafting next-generation precision medicines aimed at exploiting significant opportunities within Fibroblast Growth Factor Receptor (FGFR) biology, has recently announced participation in a series of important investor conferences.
Participation at Notable Conferences
The company will be represented at the Jefferies London Healthcare Conference, scheduled to take place...
Jefferies London Healthcare Conference
From November 19 to November 21, Tyra's CEO, Todd Harris, will engage in a fireside chat on Tuesday, November 19th, at 2:00 PM GMT. The management team will also arrange one-on-one investor meetings, fostering direct engagement with potential stakeholders.
36th Annual Piper Healthcare Conference
Tyra will also participate in the 36th Annual Piper Healthcare Conference from December 3 to December 5. Mr. Harris is set to present during a fireside chat on Wednesday, December 4th, at 10:30 AM ET. Again, the management will conduct one-on-one meetings with interested investors.
Webcast Availability
Investors and stakeholders who are unable to attend these events in person will have the opportunity to access a live and archived webcast of the fireside chats through the company's website, enabling them to stay informed about Tyra's progress and future plans.
About Tyra Biosciences
Tyra Biosciences, Inc. operates with a strong focus on developing groundbreaking precision medicines that target significant opportunities in FGFR biology. Using their advanced in-house precision medicine platform, known as SNÅP, the company can conduct rapid and precise drug designs through iterative molecular snapshots. These snapshots assist in predicting genetic alterations that are likely to cause resistance to current therapies.
Tyra has developed a unique pipeline of three clinical-stage programs targeting both oncology and genetically defined conditions. The lead precision medicine candidate, TYRA-300, represents a potential first-in-class selective FGFR3 inhibitor, specifically engineered to minimize the associated toxicities common with the inhibition of FGFR1, FGFR2, and FGFR4. This innovative approach ensures efficacy while remaining agnostic to FGFR3 gatekeeper mutations. This compound is currently under investigation for cancer treatment in the SURF301 Phase 1/2 study and for achondroplasia in the BEACH301 Phase 2 study.
Further demonstrating its commitment to addressing unmet medical needs, Tyra is also developing TYRA-200, an investigational FGFR1/2/3 inhibitor, within the SURF201 study for metastatic intrahepatic cholangiocarcinoma. Another promising candidate, TYRA-430, is being researched as an investigational FGFR4/3-biased inhibitor for cancers driven by FGF19+/FGFR4.
Tyra operates out of a modern facility in Carlsbad, California, continuing to expand its footprint in the biotechnology space.
Contact Information
The company encourages interested investors to reach out to their representative for further inquiries. Contact details are maintained within the company’s official announcements.
Frequently Asked Questions
What is Tyra Biosciences known for?
Tyra Biosciences specializes in developing next-generation precision medicines targeting large opportunities in FGFR biology.
When are the upcoming investor conferences?
Tyra management will participate in conferences from November 19-21 and December 3-5.
Who will represent Tyra at these conferences?
CEO Todd Harris will lead discussions and fireside chats at both conferences.
Where can I access the conference webcasts?
Webcasts of the fireside chats will be available on the company's website.
What is TYRA-300?
TYRA-300 is Tyra's lead precision medicine candidate, serving as a selective FGFR3 inhibitor designed to reduce toxic side effects.
